Clevudine//cas:163252-36-6 cas:163252-36-6 Clevudine
Clevudine is an antiviral drug for the treatment of hepatitis B. It is already approved for HBV in South Korea and thePhilippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.
Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, double-blind, 96 week QUASH studies) was terminated due to some myopathycases in patients. It's approval in South Korea was revoked following these findings.
Systematic (IUPAC) name | |
---|---|
1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine- 2,4-dione | |
Clinical data | |
Pregnancy cat. | |
Legal status | |
Routes | Oral |
Identifiers | |
CAS number | 69256-17-3 |
ATC code | J05AF12 [1] |
PubChem | CID 73115 |
ChemSpider | 65894 |
UNII | IN51MVP5F1 |
KEGG | D03537 |
ChEMBL | CHEMBL458875 |
Chemical data | |
Formula | C10H13FN2O5 |
Mol. mass | 260.219 g/mol |
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View